Laser-Assisted Drug Delivery.

Publisher: Wolters Kluwer Health Country of Publication: United States NLM ID: 9504371 Publication Model: Print Cited Medium: Internet ISSN: 1524-4725 (Electronic) Linking ISSN: 10760512 NLM ISO Abbreviation: Dermatol Surg Subsets: MEDLINE

Publication: 2021- : [Philadelphia] : Wolters Kluwer Health
Original Publication: New York, NY : Elsevier Science, c1995-

Drug Delivery Systems* ; Laser Therapy*/adverse effects; Dermatologic Agents/*administration & dosage ; Skin/*metabolism; Administration, Cutaneous ; Adrenergic beta-Antagonists/administration & dosage ; Aminolevulinic Acid/administration & dosage ; Aminoquinolines/administration & dosage ; Analgesics/administration & dosage ; Antibodies/administration & dosage ; Antineoplastic Agents/administration & dosage ; Ascorbic Acid/administration & dosage ; Cyclopropanes/administration & dosage ; Fluorouracil/administration & dosage ; Humans ; Imiquimod ; Immunotherapy/methods ; Methotrexate/administration & dosage ; Minoxidil/administration & dosage ; Permeability ; Photosensitizing Agents/administration & dosage ; Polyesters/administration & dosage ; RNA, Small Interfering/administration & dosage ; Timolol/administration & dosage ; Vaccines/administration & dosage

Background: Laser-assisted drug delivery (LADD) is an evolving new therapy with many possible applications as a highly targeted customizable method for distribution of drugs within the skin. LADD offers the advantages of accessibility, noninvasiveness, compliance, safety, and effectiveness.
Objective: To review the available literature regarding LADD.
Methods: A MEDLINE search was performed on LADD from 1989 to 2015, and the results are summarized. Practical applications of these procedures are also discussed.
Results: Reports of the use of ablative, nonablative, and fractional lasers as a means to increase cutaneous permeation of the topical application of medications and cosmeceuticals were found. The focus of the review was to demonstrate the variety of topical treatments that have been used with the LADD method and the multitude of future studies needed to fully characterize the best application of this evolving technology.
Conclusion: The most comprehensive review in the literature to date on LADD is provided. Further studies are needed to fully evaluate the safety, dosing, side effects, and results.

0 (Adrenergic beta-Antagonists)
0 (Aminoquinolines)
0 (Analgesics)
0 (Antibodies)
0 (Antineoplastic Agents)
0 (Cyclopropanes)
0 (Dermatologic Agents)
0 (Photosensitizing Agents)
0 (Polyesters)
0 (RNA, Small Interfering)
0 (Vaccines)
459TN2L5F5 (poly(lactide))
5965120SH1 (Minoxidil)
817W3C6175 (Timolol)
88755TAZ87 (Aminolevulinic Acid)
I7G14NW5EC (diphenylcyclopropenone)
P1QW714R7M (Imiquimod)
PQ6CK8PD0R (Ascorbic Acid)
U3P01618RT (Fluorouracil)
YL5FZ2Y5U1 (Methotrexate)

Date Created: 20160519 Date Completed: 20170403 Latest Revision: 20181202

20221213

10.1097/DSS.0000000000000556

27191783